Namyang Dairy saw a surge in its shares after claiming its Bulgaris yogurt variants can help lower the risk of COVID-19 infection. The company's day trading on Wednesday, April 14, reportedly increased.
As per The Korea Herald, Namyang Dairy’s shares once shot up by 28.68% to KRW489,000 or around $437.39 in the early morning trading. It was added that within 20 minutes after the opening bell, the company’s preferred stocks also surge by the daily allowable limit of 29.78% to reach KRW231,000.
Prior to Wednesday’s results, it was reported that the firm’s shares went up 7.19% and 6.71% on Friday and Monday, respectively. It then increased again by 8.57% on Tuesday, and this shows that Namyang Dairy’s shares have been on the rise since last weekend and continued this week.
Namyang’s COVID-19 claim
Observers are saying that the company’s surge in shares may be due to its claims that its Bulgaris yogurt lineup can help reduce the risk of getting COVID-19. Some market insiders also think that some investors may have also used information that caused the hike in the recent stock tradings.
At any rate, what triggered the sudden increase in shares of Namyang Dairy was the statement given by the company during a news conference in Seoul.
“We’re the first firm in the country that has discovered fermented dairy products are effective in preventing influenza and COVID-19 viruses,” Namyang’s chief of antiviral immune research center, Park Jong Su, said at that time. “Our experiments showed that Bulgaris helped remove the Influenza A (H1N1) virus at a 99.999 percent rate of success, and the COVID-19 at a 77.8 percent success rate.”
He added that the test of the yogurt’s effectiveness in fighting coronavirus was done using the lung cells of a monkey. As a result of this claim, people reportedly rushed out to purchase Namyang Dairy’s Bulgaris yogurts in stores.
Statement from S. Korea’s health officials
After the announcement from Namyang, the public health authorities released a statement. The agency expressed its concern over the claims.
“The latest research result has not proved to be effective in eliminating those viruses in the human body,” the Korea Disease Control and Prevention Agency stated. “Therefore, it is hard to say whether it can serve as an actual prevention or treatment measure for (the viruses).”


EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil
Elon Musk Announces Terafab: SpaceX and Tesla to Build Dual AI Chip Factories in Austin, Texas
FEMSA Cuts Jobs at Spin Fintech Unit, Refocuses Strategy on Oxxo Stores
Trump Issues 48-Hour Ultimatum to Iran Over Strait of Hormuz, Threatens Power Grid Strikes
Goldman Sachs Raises Oil Price Forecasts Amid Strait of Hormuz Disruptions
Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears
U.S. Futures Slide as Iran Denies Nuclear Talks with Washington
Oil Prices Rebound as Iran Denies U.S. Talks, Middle East Tensions Persist
J.P. Morgan Now Expects Two ECB Rate Hikes Amid Inflation Pressures
Goldman Sachs Raises ECB Rate Hike Forecast Amid Persistent Energy-Driven Inflation
Air Canada Express Plane Collides with Ground Vehicle at LaGuardia Airport
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group
Volkswagen CEO Urges Germany to Adopt China's Industrial Discipline Amid Major Restructuring
Amazon's "Transformer" Phone: Can It Succeed Where Fire Phone Failed?
Asian Stocks Gain Amid Iran Conflict Uncertainty 



